246 related articles for article (PubMed ID: 17485900)
1. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Ito Y; Tokudome N; Sugihara T; Takahashi S; Hatake K
Breast Cancer; 2007; 14(2):156-62. PubMed ID: 17485900
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.
Paul B; Trovato JA; Thompson J
Am J Health Syst Pharm; 2008 Sep; 65(18):1703-10. PubMed ID: 18768996
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
7. [Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Pikó B
Magy Onkol; 2009 Dec; 53(4):369-75. PubMed ID: 20071309
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
11. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a sword with two edges.
Kopper L
Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib and breast cancer: current indications and outlook for the future.
Moreira C; Kaklamani V
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1171-82. PubMed ID: 20735304
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
18. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib for advanced or metastatic breast cancer.
Opdam FL; Guchelaar HJ; Beijnen JH; Schellens JH
Oncologist; 2012; 17(4):536-42. PubMed ID: 22477724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
